Ten facts about the format.
The detail behind what we showed you.
You have the story. This is the layer underneath it: the numbers, the specifications, and the studies. Nothing here is a new argument for why the format matters. It is the evidence for what you already heard.
HOW IT GOES IN
01
It disperses in the mouth in under five seconds.
No pill to hide in food, no paste to fight over, and no question afterward about whether the dose went down. That holds the same way for a five-day course and for a daily chronic regimen, which is where treatment plans usually fail.
02
It absorbs across the mucosa, so it skips digestion entirely.
The drug crosses the lining of the cheek directly into the bloodstream. It does not have to survive the stomach, because it is absorbed before digestion starts.
03
It is stable in your hand and gone in their mouth.
The tablet handles, packages, and ships without special conditions. It is engineered to disintegrate on contact with the saliva composition, not from being held, dropped, or left on a counter.
WHAT IT DOES TO THE MOLECULE
04
It is freeze-dried, not compressed.
The speed is not a coating or an additive. Freeze-drying leaves a high-porosity matrix: an open structure that takes on saliva the moment it makes contact. The tablet is mostly structured empty space, which makes the speed a manufacturing outcome rather than a formulation trick.
05
It carries up to 400 mg insoluble or 60 mg soluble.
This is the number most often used to rule the format out, and it is usually used wrong. Our platform uses the free-acid form rather than the salt form, which typically means meaningfully less active drug is needed to reach the same target. Before you disqualify a compound, run the free-base math.
06
It takes roughly 20 to 60 percent less active drug per dose to reach the same target.
Gastric protectants are not required, which removes a formulation layer and its cost. Fewer excipients at a lower drug load also means less material to account for in the safety margin.
07
Tablets are shelf stable for up to three years.
No special storage conditions and no cold chain.
WHETHER IT IS REAL
08
The platform has more than thirty years in human medicine.
More than 35 approved human products across pain, allergy, and nausea. More than 20 issued patents across more than 60 countries. Roughly 1.2 billion tablets a year. ODT holds seven animal-health-specific patents on top of it.
09
Six actives across four species have already been through the platform.
Proof of concept is established in equine, canine, feline, and bovine. Actives delivered: ivermectin, flunixin, detomidine, acepromazine, clenbuterol, marbofloxacin.
10
The lead program runs through an existing NADA, on an established line.
Not a novel regulatory pathway. Production runs on dedicated freeze-drying equipment at the Catalent facility in Swindon, England, and ODT retains manufacturing rights across the platform.
Fact 1 is the reason the company exists. The other nine are why it holds up.
Three formats, measured the same way.
BEHIND FACT 4: How it’s made
Four steps, start to tablet.
01
Solution or suspension.
The drug goes into a minimum volume of liquid.
02
Fill.
That liquid is dosed through a filling nozzle into blister pockets.
03
Freeze.
Rapid freezing at low temperature locks the drug into an ice matrix.
04
Freeze-dry.
The ice is removed by sublimation. Every place ice used to be is now a pore.
The lead omeprazole program runs the full sequence in production today: bulk mix, dose, freeze, seal, dry, followed by blister sealing and secondary packaging. This is a documented production process on dedicated equipment, not a bench protocol waiting to be scaled.
THREE PATHS TO REVENUE
How this becomes a deal.
Three shapes, and a structure that lets you buy one asset without buying the company.
One asset at a time, cleanly. Seven animal-health-specific patents, layered on a platform protected by more than 20 issued patents across more than 60 countries. A holding company owns platform development and manufacturing rights and licenses specific species and indication rights down into a separate entity for each asset. The practical effect is that a single program can be acquired on its own, without acquiring the platform, and without disturbing manufacturing or the other programs in development. Most companies at this stage cannot offer that.
Sometimes we look like a contract manufacturer, sometimes like a biotech, sometimes like a co-investor. The model flexes to what you are bringing. What does not flex is that manufacturing stays with us in all three, which is fact 10. Most companies fit more than one of these, and the shape usually comes out of the first real conversation rather than the first meeting.
Capacity for fully outsourced development work is limited to a small number of concurrent programs. The earlier we talk, the more of it is open.
Send us a molecule.
The fastest way to find out whether this is real for you is to give us something specific.
Send a compound and a target dose. We will come back with the free-base math, an honest read on whether the format carries it, and a first-pass shape for what development would look like. If the answer is no, you will get that answer too, and faster than a study would give it to you.
Tony Simpson
Thomas Overbay, DVM